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Case report
  A 75-year-old woman presented to our department to 
undergo a stress myocardial perfusion imaging study (MPS) 
with Tc99m-sestamibi as part of  cardiac clearance before a 
diverting end sigmoid colostomy. During the scan, inciden-
tal focal uptake was noted in the left upper anterior chest, 
initially felt to be within the left breast. Single-photon CT 
images (SPECT) of  the chest were subsequently obtained 
during the same visit for improved localization of  this focus. 
The focus was actually found to be in the left chest wall, 
likely in the anterior left rib adjacent to the myocardium.  
Additional foci were noted within the spine, left upper lung, 
and hilum (Fig. 1). 
A review of  medical records from another institution, in 
addition to correlation with outside F18-fluorodeoxyglucose 
(FDG) positron-emission tomography (PET/CT), MRI, 
and bone scans performed earlier the same year, indicated 
that these foci most likely represented metastases from re-
current thyroid cancer (Figs. 2-4). After further in-hospital 
chart review, the patient was indeed found to have a history 
of  organ-confined follicular thyroid cancer, surgically 
treated with total thyroidectomy 9 years ago, followed by 
radioiodine ablation with 75 mCi of  I-131 sodium iodide. 
The patient was subsequently lost to followup. 
Discussion
 MPS with Tc99m-sestamibi has become one of  the most 
frequently ordered medical imaging studies. This comes as 
no surprise, considering the high prevalence of  coronary 
artery disease. However, as with all imaging studies, inci-
dental findings must be noted. This is especially true for 
MPS, knowing that sestamibi is a tumor-imaging agent 
with applications in mammoscintigraphy, parathyroid im-
aging, and whole-body tumor imaging in thyroid cancer 
patients with suspected noniodine-avid disease (1). 
The validity of  Tc99m-sestamibi for evaluation of  recur-
rent and metastatic differentiated thyroid carcinoma has 
been well established (2-4). The diagnostic yield for Tc99m-
sestamibi whole-body imaging is greatest in the evaluation 
of  patients with suspected recurrent differentiated thyroid 
carcinoma when the thyroglobulin levels are elevated de-
spite no evidence for recurrence on whole-body radioiodine 
scan (5). This is in order to exclude evidence of  active ma-
lignancy that may have evolved into poorly differentiated 
or dedifferentiated disease, although (given its superior spa-
tial resolution) FDG-PET remains the modality of  choice 
for evaluation of  noniodine-avid thyroid cancer recurrence 
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A 75-year-old woman presented to our department for a stress myocardial perfusion imaging study with 
Tc99m-sestamibi. Incidental focal uptake, found in the left upper anterior chest, was initially felt to be 
located in the left breast. After additional single-photon CT imaging was performed the same day, ex-
tracardiac foci within the ribs, spine, and left lung (worrisome for active metastases) were shown to be 
present, with the initial focus located within a left rib rather than a breast. A review of  previous radio-
graphic and nuclear imaging studies confirmed metastatic disease from recurrent follicular thyroid can-
cer. Atypical focal extracardiac activity must be closely scrutinized for the possibility of  malignancy, as 
Tc99m-sestamibi (in addition to being myocardium-avid) is tumor-avid.  
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Figure 2. 
Tc99m-MDP 
bone scan of the 
same patient 
four months 
before the MPS 
demonstrated a 
photopenic fo-
cus in the T5 
vertebral body 
(arrow) consis-
tent with local 
bone destruc-
tion. A bone 
scan failed to 
demonstrate 
any bone find-
ings in the left 
anterior chest.
Figure 3. F18-FDG PET/CT study 4 months before the MPS demonstrating the 
left upper lung (A), left 5th rib (B), and right T5 vertebral lesions (C) with subtle 
increase in F18-FDG uptake.
Figure 1. A 75-year-old female was referred to the nuclear medicine department for cardiac evaluation with Tc99m-Sestamibi 
MPS as part of cardiac clearance before a diverting end sigmoid colostomy. The patient was found to have abnormal focal 
uptake adjacent to the anterior wall of the left ventricle (A, B, C). Additional SPECT images in the axial, sagittal, and coronal 
projections were acquired during the same visit. These images localized this focus to the left fifth rib. Additional foci of sesta-
mibi accumulation within the left upper lung field (D), left hilum (E), and right lateral aspect of the T5 vertebra (F) were demon-
strated. Correlation with prior CT and FDG18-PET/CT studies confirmed these foci to be aggressive osteolytic bone metasta-
ses and lung metastasis.  
(6). Hence, it should come as no surprise that metastatic 
thyroid cancer, along with other abnormal foci of  extracar-
diac sestamibi uptake (7), may be visualized on a routine 
MPS. Therefore, the interpreting radiologist, nuclear medi-
cine physician, or cardiologist should always thoroughly 
survey the raw images on MPS for unusual focal extracar-
diac activity, since such a finding could potentially represent 
incidental malignancy, which unfortunately in this patient 
was attributed to bone metastasis.
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Figure 4. T2-weighted MRI demonstrates the T5 vertebral 
metastasis with destruction of the body and posterior ele-
ments and spinal cord impingement (A, B). 
